Scholarlink

<p>Clinical treatment for infections and illnesses caused by multidrug-resistant bacteria is still lacking. Efflux pumps serve as one of the key mechanisms for bacteria to resist antibiotics, facilitating the transfer of antibiotics from the interior of their cells to the external surroundings. Inhibiting these pumps could be an intriguing approach to regaining antibiotic efficacy in multi-drug resistance (MDR) bacterial infections. The ongoing study endeavors to identify recently FDA-approved drugs that could be repurposed as good candidates against the AcrB subunit of <i>Escherichia coli's</i> multidrug efflux pump. Through the utilization of structure-guided approaches, this study was conducted using the AcrB subunit (PDB: 7B8S) to elucidate the inhibitory effects of selected FDA-approved drugs, using techniques such as molecular docking, MM/GBSA, and molecular dynamics. Among 202, 78 drugs underwent scrutiny for their interaction with the AcrB protein and 3 drugs demonstrated superior binding conformations (dock score: ≥ − 8.0) marked by favorable energetic profiles within the target's active site which were subsequently subjected to 200-ns molecular dynamics (MD) simulation. The molecular docking results have shown favored binding conformation of 3 drugs in the active site of the efflux pump of Gram-negative bacteria. The molecular dynamics studies results have shown the stability of tenapanor, lumateperone tosylate, and lasmiditan in the active site of the AcrB protein of <i>E. coli</i>. The identified drugs can be repurposed against resistant bacterial infections through the inhibition of efflux pumps with further experimental validation.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of recently FDA-approved drugs as a repurposing candidate against multidrug efflux pump subunit AcrB of Escherichia coli: a molecular docking, MM/GBSA, molecular dynamics approach

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Debanjan Dey,
  • Anoop Kumar

摘要

Clinical treatment for infections and illnesses caused by multidrug-resistant bacteria is still lacking. Efflux pumps serve as one of the key mechanisms for bacteria to resist antibiotics, facilitating the transfer of antibiotics from the interior of their cells to the external surroundings. Inhibiting these pumps could be an intriguing approach to regaining antibiotic efficacy in multi-drug resistance (MDR) bacterial infections. The ongoing study endeavors to identify recently FDA-approved drugs that could be repurposed as good candidates against the AcrB subunit of Escherichia coli's multidrug efflux pump. Through the utilization of structure-guided approaches, this study was conducted using the AcrB subunit (PDB: 7B8S) to elucidate the inhibitory effects of selected FDA-approved drugs, using techniques such as molecular docking, MM/GBSA, and molecular dynamics. Among 202, 78 drugs underwent scrutiny for their interaction with the AcrB protein and 3 drugs demonstrated superior binding conformations (dock score: ≥ − 8.0) marked by favorable energetic profiles within the target's active site which were subsequently subjected to 200-ns molecular dynamics (MD) simulation. The molecular docking results have shown favored binding conformation of 3 drugs in the active site of the efflux pump of Gram-negative bacteria. The molecular dynamics studies results have shown the stability of tenapanor, lumateperone tosylate, and lasmiditan in the active site of the AcrB protein of E. coli. The identified drugs can be repurposed against resistant bacterial infections through the inhibition of efflux pumps with further experimental validation.

Graphical Abstract